Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer

References

• Aeschbach D, Lockyer BJ, Dijk DJ, et al. (2009). Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther 86:378–82.
   PubMed Web of Science ®Google Scholar
• Andréo MA, Rufino IM, Ubaldo DCODO, et al. (2016). Performance evaluation of Cryo Laser Phoresis technique as biophysical method to promote diclofenac sodium cutaneous perfusion. Braz J Pharm Sci 52:69–76.
   Web of Science ®Google Scholar
• Babu RJ, Dayal P, Singh M. (2008). Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug DelivDeliv 15:381–8.
   Google Scholar
• Bizzarri M, Proietti S, Cucina A, Reiter RJ. (2013). Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 17:1483–96.
   PubMed Web of Science ®Google Scholar
• Bonizzoni E. (2007). Medical apparatus for cutaneous administration of medicaments. European Patent Application EP 1752190(A1), 14 Feb 2007.
   Google Scholar
• Ciortea R, Costin N, Braicu I, et al. (2011). Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer Res 31:2637–43.
   PubMed Web of Science ®Google Scholar
• De Souza FI, Cristante AF, Marcon RM, et al. (2013). Transdermal monosialoganglioside with laser in the treatment of spinal cord lesion in rats. Acta Ortop Bras 21:87–91.
   PubMed Web of Science ®Google Scholar
• Dumont M, Lanctot V, Cadieux-Viau R, Paquet J. (2012). Melatonin production and light exposure of rotating night workers. Chronobiol Int 29:203–10.
   PubMed Web of Science ®Google Scholar
• Flo A, Calpena AC, Halbaut L, et al. (2016). Melatonin delivery: transdermal and transbuccal evaluation in different vehicles. Pharm Res 33:1615–27.
   PubMed Web of Science ®Google Scholar
• Gao Y, Xiao X, Zhang C, et al. (2016). Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-kappaB/iNOS signaling pathways. J Pineal Res 62.
   Web of Science ®Google Scholar
• Gonzalez A, Gonzalez-Gonzalez A, Alonso-Gonzalez C, et al. (2017). Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF. Oncol Rep 37:2433–2440.
   PubMed Web of Science ®Google Scholar
• Hill SM, Cheng C, Yuan L, et al. (2013). Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. CASSci 6:125–33.
   Google Scholar
• Kelleher FC, Rao A, Maguire A. (2014). Circadian molecular clocks and cancer. Cancer Lett 342:9–18.
   PubMed Web of Science ®Google Scholar
• Kim KY, Lee E, Kim YJ, Kim J. (2016). The association between artificial light at night and prostate cancer in Gwangju City and South Jeolla Province of South Korea. Chronobiol Int 34:203–211.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Parrott KA, Ayres JW, Sack RL. (1994). Preliminary evaluation of transdermal delivery of melatonin in human subjects. Res Commun Mol Pathol Pharmacol 85:337–46.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Fumagalli L, Brivio F, et al. (2006). Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents 20:29–35.
   PubMed Web of Science ®Google Scholar
• Luchetti F, Canonico B, Betti M, et al. (2010). Melatonin signaling and cell protection function. Faseb J 24:3603–24.
   PubMed Web of Science ®Google Scholar
• Ma Z, Yang Y, Fan C, et al. (2016). Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget 7:46768–84.
   PubMed Web of Science ®Google Scholar
• Mao L, Summers W, Xiang S, et al. (2016). Melatonin represses metastasis in Her2-postive human breast cancer cells by suppressing RSK2 expression. Mol Cancer Res 14:1159–69.
   PubMed Web of Science ®Google Scholar
• Marwah H, Garg T, Goyal AK, Rath G. (2016). Permeation enhancer strategies in transdermal drug delivery. Drug Deliv 23:564–78.
   PubMed Web of Science ®Google Scholar
• Miller ET, Chamie K, Kwan L, et al. (2016). Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. Cancer Med 6:163–172.
   PubMed Web of Science ®Google Scholar
• Najafi M, Shirazi A, Motevaseli E, et al. (2017). Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology. [Epub ahead of print]. doi:10.1007/s10787-017-0332-5
   Web of Science ®Google Scholar
• Oh HJ, Oh YK, Kim CK. (2001). Effects of vehicles and enhancers on transdermal delivery of melatonin. Int J Pharm 212:63–71.
   PubMed Web of Science ®Google Scholar
• Paroni R, Terraneo L, Bonomini F, et al. (2014). Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res 57:43–52.
   PubMed Web of Science ®Google Scholar
• Poorthuis MH, Vernooij RW, Van Moorselaar RJ, De Reijke TM. (2017). First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials. BJU Int 119:831–845.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Brzezinski A, et al. (2011). Melatonin, immune function and cancer. EMI Discov 5:109–23.
   Google Scholar
• Srinivasan V, Spence DW, Pandi-Perumal SR, et al. (2008). Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7:189–203.
   PubMed Web of Science ®Google Scholar
• Tam CW, Shiu SY. (2011). Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res 51:297–312.
   PubMed Web of Science ®Google Scholar
• Terraneo L, Virgili E, Caretti A, et al. (2014). In vivo hyperoxia induces hypoxia-inducible factor-1alpha overexpression in LNCaP tumors without affecting the tumor growth rate. Int J Biochem Cell Biol 51:65–74.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Fu Y, et al. (2016a). CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate 76:140–50.
   PubMed Web of Science ®Google Scholar
• Wang RX, Liu H, Xu L, et al. (2016b). Melatonin downregulates nuclear receptor RZR/RORgamma expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. Oncol Lett 12:897–903.
   PubMed Web of Science ®Google Scholar
• Zhao M, Wan J, Zeng K, et al. (2016). The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: a retrospective study. J Cancer 7:831–6.
   PubMed Web of Science ®Google Scholar